Phase II Study of Icotinib Combined With Whole Brain Radiotherapy in Treating Patients With Brain Metastases From Non-Small Cell Lung ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2012-2014

ABSTRACT

The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC. Detailed Description Brain metastases occur in 25-40% of patients with non-small cell lung cancer (NSCLC). It is one of the primary reasons resulting in treatment failure and the death. Whole-brain radiation therapy (WBRT) is the standard approach to the treatment of multiple brain metastases from NSCLC. Regardless of the treatment of brain metastases by WBRT combined with systemic chemotherapy,outcomes of NSCLC with brain metastases are still very poor. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC. Icotinib shows nearly the same effect as gefitinib in advanced NSCLC patients failed with chemotherapy. More... »

URL

https://clinicaltrials.gov/show/NCT01514877

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.\n\nDetailed Description\nBrain metastases occur in 25-40% of patients with non-small cell lung cancer (NSCLC). It is one of the primary reasons resulting in treatment failure and the death. Whole-brain radiation therapy (WBRT) is the standard approach to the treatment of multiple brain metastases from NSCLC. Regardless of the treatment of brain metastases by WBRT combined with systemic chemotherapy,outcomes of NSCLC with brain metastases are still very poor. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC. Icotinib shows nearly the same effect as gefitinib in advanced NSCLC patients failed with chemotherapy.", 
    "endDate": "2014-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01514877", 
    "keywords": [
      "Phase II", 
      "whole-brain", 
      "non small cell lung cancer", 
      "efficacy", 
      "toxicity", 
      "Treating", 
      "patient", 
      "brain metastasis", 
      "NSCLC", 
      "brain", 
      "Neoplasm Metastasis", 
      "Non-Small-Cell Lung Carcinoma", 
      "primary reason", 
      "treatment failure", 
      "death", 
      "radiation therapy", 
      "standard approach", 
      "systemic chemotherapy", 
      "epidermal growth factor receptor tyrosine kinase inhibitor", 
      "EGFR", 
      "blood-brain barrier", 
      "antitumor activity", 
      "same effect", 
      "gefitinib", 
      "advanced non-small cell lung cancer", 
      "Drug Therapy"
    ], 
    "name": "Phase II Study of Icotinib Combined With Whole Brain Radiotherapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01514877"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417397.f", 
        "type": "Organization"
      }
    ], 
    "startDate": "2012-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s00280-015-2760-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031290433", 
          "https://doi.org/10.1007/s00280-015-2760-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01514877"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01514877'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01514877'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01514877'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01514877'


 

This table displays all metadata directly associated to this object as RDF triples.

49 TRIPLES      16 PREDICATES      42 URIs      35 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01514877 schema:about anzsrc-for:3142
2 schema:description The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC. Detailed Description Brain metastases occur in 25-40% of patients with non-small cell lung cancer (NSCLC). It is one of the primary reasons resulting in treatment failure and the death. Whole-brain radiation therapy (WBRT) is the standard approach to the treatment of multiple brain metastases from NSCLC. Regardless of the treatment of brain metastases by WBRT combined with systemic chemotherapy,outcomes of NSCLC with brain metastases are still very poor. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC. Icotinib shows nearly the same effect as gefitinib in advanced NSCLC patients failed with chemotherapy.
3 schema:endDate 2014-07-01T00:00:00Z
4 schema:keywords Drug Therapy
5 EGFR
6 NSCLC
7 Neoplasm Metastasis
8 Non-Small-Cell Lung Carcinoma
9 Phase II
10 Treating
11 advanced non-small cell lung cancer
12 antitumor activity
13 blood-brain barrier
14 brain
15 brain metastasis
16 death
17 efficacy
18 epidermal growth factor receptor tyrosine kinase inhibitor
19 gefitinib
20 non small cell lung cancer
21 patient
22 primary reason
23 radiation therapy
24 same effect
25 standard approach
26 systemic chemotherapy
27 toxicity
28 treatment failure
29 whole-brain
30 schema:name Phase II Study of Icotinib Combined With Whole Brain Radiotherapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
31 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01514877
32 schema:sdDatePublished 2019-03-07T15:24
33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
34 schema:sdPublisher N3b98b4f5748f45869ee14810b89c78d9
35 schema:sponsor https://www.grid.ac/institutes/grid.417397.f
36 schema:startDate 2012-01-01T00:00:00Z
37 schema:subjectOf sg:pub.10.1007/s00280-015-2760-5
38 schema:url https://clinicaltrials.gov/show/NCT01514877
39 sgo:license sg:explorer/license/
40 sgo:sdDataset clinical_trials
41 rdf:type schema:MedicalStudy
42 N3b98b4f5748f45869ee14810b89c78d9 schema:name Springer Nature - SN SciGraph project
43 rdf:type schema:Organization
44 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
45 rdf:type schema:DefinedTerm
46 sg:pub.10.1007/s00280-015-2760-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031290433
47 https://doi.org/10.1007/s00280-015-2760-5
48 rdf:type schema:CreativeWork
49 https://www.grid.ac/institutes/grid.417397.f schema:Organization
 




Preview window. Press ESC to close (or click here)


...